Genentech Kadcyla 1st Targeted Therapy to Show Significant Overall Survival Benefit in HER2+ EarlyBreast Cancer

 Phase III KATHERINE results reinforce Kadcyla as the standard of care for this population, with more than 82,000 people treated to date –

– Long-term data also showed continued benefit in invasive disease-free survival for adjuvant Kadcyla compared to Herceptin in this study –

– These data will be presented as an oral presentation at the 2023 San Antonio Breast Cancer Symposium and included in the official press program –

https://www.biospace.com/article/releases/genentech-s-kadcyla-is-the-first-targeted-therapy-to-show-significant-overall-survival-benefit-in-people-with-her2-positive-early-stage-breast-cancer-with-residual-invasive-disease-after-neoadjuvant-treatment/